(600812)"North China Pharmaceutical Company Ltd."Announcement on Risk Warning in Stock Trading
Filed with SSE · Stock code 600812 · · 3 pages · Chinese
Summary by 6ix AI
North China Pharmaceutical Company Ltd. has issued a risk warning regarding stock trading due to significant price fluctuations in recent trading days, which may lead to rapid declines after sharp increases. The company reported a substantial decline in its operating performance for the first half of the year, with revenue and net profit both decreasing significantly compared to the previous year. Additionally, the company's price-to-earnings ratio is notably higher than that of its industry peers, indicating potential market speculation risks.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
North China Pharmaceutical Company Ltd. on 6ix
Story so far
- (600812)"North China Pharmaceutical Company Ltd."Announcement on Abnormal Fluctuations in Stock Trading
- Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Hebei Jurisdiction and 2026 Semi-annual Collective Performance Briefing
- Announcement on Providing Guarantees for Subsidiaries
Earlier from North China Pharmaceutical
- (600812)"North China Pharmaceutical Company Ltd."Announcement on Abnormal Fluctuations in Stock Trading
- Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Hebei Jurisdiction and 2026 Semi-annual Collective Performance Briefing
- Announcement on Providing Guarantees for Subsidiaries
- Announcement on Obtaining Notice of Approval for Drug Supplementary Application by a Subordinate Company
- Semi-annual Report for 2026
Follow North China Pharmaceutical into a list and get an email when it puts out news.
Follow North China Pharmaceutical